Mastering Anti-CD38 Therapy in Multiple Myeloma Care: Case-Based Education for Advanced Practitioners and Oncology Nurses

Please visit answersincme.com/860/2026-MC-002375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO; and Krina Patel, MD, MSc. In this activity, experts in multiple myeloma discuss key treatment considerations and personalization strategies for anti-CD38 therapy. Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of key data supporting anti-CD38–based regimens in patients with multiple myeloma (MM); Outline evidence-based strategies to manage toxicities associated with anti-CD38–based therapies; Identify key considerations for integrating anti-CD38 monoclonal antibodies into treatment plans for patients with MM; and Apply practical, patient-centered care considerations to optimize outcomes with anti-CD38 monoclonal antibodies for patients with MM.